- Home
- ICCC vs NTRB Comparison
ICCC vs NTRB Comparison
Compare ICCC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- NTRB
- Stock Information
- Founded
- ICCC 1982
- NTRB 2016
- Country
- ICCC United States
- NTRB United States
- Employees
- ICCC N/A
- NTRB N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- ICCC Health Care
- NTRB Health Care
- Exchange
- ICCC Nasdaq
- NTRB Nasdaq
- Market Cap
- ICCC 60.1M
- NTRB 71.8M
- IPO Year
- ICCC 1987
- NTRB N/A
- Fundamental
- Price
- ICCC $5.60
- NTRB $7.30
- Analyst Decision
- ICCC
- NTRB Buy
- Analyst Count
- ICCC 0
- NTRB 1
- Target Price
- ICCC N/A
- NTRB $13.00
- AVG Volume (30 Days)
- ICCC 6.8K
- NTRB 32.8K
- Earning Date
- ICCC 11-12-2025
- NTRB 09-09-2025
- Dividend Yield
- ICCC N/A
- NTRB N/A
- EPS Growth
- ICCC N/A
- NTRB N/A
- EPS
- ICCC 0.20
- NTRB N/A
- Revenue
- ICCC $28,274,756.00
- NTRB $2,578,059.00
- Revenue This Year
- ICCC N/A
- NTRB $560.75
- Revenue Next Year
- ICCC N/A
- NTRB $588.39
- P/E Ratio
- ICCC $29.40
- NTRB N/A
- Revenue Growth
- ICCC 21.75
- NTRB 42.92
- 52 Week Low
- ICCC $3.34
- NTRB $2.98
- 52 Week High
- ICCC $7.60
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- ICCC 35.75
- NTRB 58.75
- Support Level
- ICCC $5.59
- NTRB $6.69
- Resistance Level
- ICCC $6.42
- NTRB $7.48
- Average True Range (ATR)
- ICCC 0.27
- NTRB 0.50
- MACD
- ICCC -0.07
- NTRB 0.15
- Stochastic Oscillator
- ICCC 0.71
- NTRB 86.30
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.